WHAT IS CLAIMED IS:

1. A method of treatment of a cancer, the method comprising the steps of

administering EC145 to a patient; and

administering to the patient one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition.

2. The method of claim 1 wherein the additional chemotherapeutic agent is a taxane.

3. The method of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

4. The method of claim 3 wherein the additional chemotherapeutic agent is docetaxel.

5. The method of claim 3 wherein the additional chemotherapeutic agent is paclitaxel.

6. The method of claim 1 wherein the cancer is an epithelial cancer.

7. The method of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The method of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The method of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The method of claim 1 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The method of claim 1 wherein the EC145 and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The method of claim 11 wherein the effective amounts range from about 10 μg/kg to about 100 μg/kg of patient body weight.

15. The method of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

administering to the patient a dose of docetaxel over one hour on day one of the three week cycle of therapy.

32. The method of claim 31 wherein the dose of EC145 is 2.5 mg.

33. The method of claim 31 wherein the dose of docetaxel is 75 mg/m^2 of body surface area.

AMENDED CLAIMS
received by the International Bureau on 21 May 2012(21.05.2012)

WHAT IS CLAIMED IS:

1. A method of treatment of a cancer, the method comprising the steps of administering EC145 to a patient; and

administering to the patient one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

2. The method of claim 1 wherein the additional chemotherapeutic agent is a taxane.

3. The method of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

4. The method of claim 3 wherein the additional chemotherapeutic agent is docetaxel.

5. The method of claim 3 wherein the additional chemotherapeutic agent is paclitaxel.

6. The method of claim 1 wherein the cancer is an epithelial cancer.

7. The method of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The method of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The method of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The method of claim 1 wherein the additional chemotherapeutic agent is administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The method of claim 1 wherein the EC145 and the chemotherapeutic agent are administered in therapeutically effective amounts.

12. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The method of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The method of claim 11 wherein the effective amounts range from about 10 $\mu g/kg$ to about 100 $\mu g/kg$ of patient body weight.

15. The method of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The method of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

18. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The method of claim 1 wherein the EC145 and the additional chemotherapeutic agent are administered at doses lower than their maximum tolerable doses.

20. A kit comprising EC145 and one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is a taxane.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is docetaxel.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is paclitaxel.

25. The kit of claim 20 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of claim 20 wherein the EC145 is in the form of a reconstitutable lyophilizate.

30. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

31. A method of treatment of non-small cell lung cancer, the method comprising the steps of

administering a dose of EC145 to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and

administering to the patient a dose of docetaxel over one hour on day one of the three week cycle of therapy.

32. The method of claim 31 wherein the dose of EC145 is 2.5 mg.

33. The method of claim 31 wherein the dose of docetaxel is 75 mg/m^2 of body surface area.

Claims

1. Use of EC145 in the manufacture of a medicament for the treatment of a cancer in a patient, wherein

the medicament is to be administered with one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition; and wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

2. The use of claim 1 wherein the additional chemotherapeutic agent is a taxane.

3. The use of claim 2 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

4. The use of claim 3 wherein the additional chemotherapeutic agent is docetaxel.

5. The use of claim 3 wherein the additional chemotherapeutic agent is paclitaxel.

6. The use of claim 1 wherein the cancer is an epithelial cancer.

7. The use of claim 6 wherein the epithelial cancer is an ovarian, an endometrial, or a non-small cell lung cancer.

8. The use of claim 7 wherein the epithelial cancer is an ovarian cancer.

9. The use of claim 7 wherein the epithelial cancer is a non-small cell lung cancer.

10. The use of claim 1 wherein the additional chemotherapeutic agent is to be administered at a dose that is 50 to 80% of the maximum tolerated dose for the chemotherapeutic agent.

11. The use of claim 1 wherein the EC145 and the chemotherapeutic agent are to be administered in therapeutically effective amounts.

12. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 500 mg/m^2 of body surface area.

13. The use of claim 11 wherein the effective amounts range from about 1 $\mu g/m^2$ to about 300 mg/m^2 of body surface area.

14. The use of claim 11 wherein the effective amounts range from about 10 $\mu g/kg$ to about 100 $\mu g/kg$ of patient body weight.

15. The use of claim 1 wherein the cancer is a platinum-resistant ovarian cancer.

16. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

17. The use of claim 1 wherein the EC145 is in the form of a reconstitutable lyophilizate.

18. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

19. The use of claim 1 wherein the EC145 and the additional chemotherapeutic agent are to be administered at doses lower than their maximum tolerable doses.

20. A kit comprising EC145 and one or more additional chemotherapeutic agents having a mode of action of microtubule disassembly inhibition.

21. The kit of claim 20 wherein the additional chemotherapeutic agent is a taxane.

22. The kit of claim 21 wherein the additional chemotherapeutic agent is selected from the group consisting of docetaxel and paclitaxel.

23. The kit of claim 22 wherein the additional chemotherapeutic agent is docetaxel.

24. The kit of claim 22 wherein the additional chemotherapeutic agent is paclitaxel.

25. The kit of claim 20 wherein the EC145 and the chemotherapeutic agent are in therapeutically effective amounts.

26. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile containers or packages.

27. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 90% based on weight percentage.

28. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent have a purity of at least 95% based on weight percentage.

29. The kit of claim 20 wherein the EC145 is in the form of a reconstitutable lyophilizate.

30. The kit of claim 20 wherein the EC145 and the additional chemotherapeutic agent are in sterile, pyrogen-free aqueous solutions.

31. Use of a dose of EC145 in the manufacture of a medicament for treatment of non-small cell lung cancer, wherein

the medicament is to be administered to a patient in an intravenous bolus injection two days a week during weeks one and two of a three week cycle of therapy; and

wherein the medicament is to be administered with a dose of docetaxel over one hour on day one of the three week cycle of therapy.

32. The use of claim 31 wherein the dose of EC145 is 2.5 mg.

33. The use of claim 31 wherein the dose of docetaxel is 75 mg/m^2 of body surface area.